Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

Health Canada approves Abbott’s sensor-based glucose monitoring technology, FreeStyle Libre 2 for adults and children with diabetes

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Philips SmartHeart Wins FDA Clearance for...

Philips announced that it has received FDA 510(k) clearance...

AIQ Solutions Wins AMA CPT Code...

AIQ Solutions has announced a major step forward in...

Daiichi Sankyo, GAIA Partner on Lipodia...

Pharmaceutical companies are increasingly integrating digital health tools with...

Abbott announced its next-generation, sensor-based glucose monitoring technology, FreeStyle Libre 2, received approval fromHealth Canada for adults and children (4 and older) with diabetes. With new features such as optional, real-time alarms that measure glucose levels every minute, FreeStyle Libre 2 gives users the option to be alerted in real-time of critical events such as hypoglycemia (low glucose levels) or hyperglycemia (high glucose levels).

The wearable technology, which eliminates the need for painful fingersticks, also provides people with diabetes with excellent accuracy and actionable information to better manage their condition, and will be priced at the same cost as the current FreeStyle Libre system.

“For the millions of Canadians with diabetes, Abbott’s next-generation FreeStyle Libre 2 system expands on the life-changing capabilities of our original FreeStyle Libre system with enhanced accuracy, optional alarms and now available for children,” said Marie-Flore Nabor, general manager of Abbott’s diabetes care business in Canada. “This latest technology will transform the way diabetes is currently managed. The FreeStyle Libre 2 is designed to simplify this often complicated-to-manage condition and is accessible and affordable to people with diabetes in Canada.”

As the world leader in sensor-based glucose monitoring, Abbott continues to transform how people with diabetes test their glucose levels. Using Bluetooth technology, the FreeStyle Libre 2 system automatically alerts users when their glucose is high or low without needing to scan the sensor.

The FreeStyle Libre 2 sensor is worn on the back of the upper arm for up to 14 days and measures glucose every minute to help users and their healthcare providers make informed treatment decisions. With a one-second scan using FreeStyle LibreLink, a smartphone app,8 or handheld reader, users can see their glucose reading, trend arrow and eight-hour history. Users can also share data with their physicians or family members via the LibreLinkUp mobile app.

Abbott’s FreeStyle Libre 2 system utilizes the same proprietary wired enzyme technology as the FreeStyle Libre system, which was the first to remove painful fingersticks and is associated with better glucose control, decreased time in hypoglycemia and hyperglycemia, more time in optimal glucose range, and improved HbA1C11.

“Adding an alarm to this glucose sensing technology is definitely a major step to help people with diabetes live more confidently with less fear of high or low glucose levels,” said Dr. Bruce Perkins, M.D., director, Leadership Sinai Centre for Diabetes and Clinician-Scientist, University of Toronto. “We have seen from research with similar technologies that this kind of innovation can improve glucose level control, and even prevent emergency room visits and hospitalizations. For kids and adults alike, it means less pain from fingersticks, much greater insight into patterns, and much more reassurance.”

MEDICAL FAIR ASIA 2026

Latest stories

Related stories

Philips SmartHeart Wins FDA Clearance for AI Cardiac MR

Philips announced that it has received FDA 510(k) clearance...

AIQ Solutions Wins AMA CPT Code for TRAQinform IQ Platform

AIQ Solutions has announced a major step forward in...

Daiichi Sankyo, GAIA Partner on Lipodia Digital Therapeutics

Pharmaceutical companies are increasingly integrating digital health tools with...

Medtronic Expands Strategic Alliance with GE HealthCare

Medtronic has entered into a multi-year renewal and significant...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »